Qingzhong Hu

List of Publications by Year
in descending order

42	1,315	304602	345118
papers	citations	22 h-index	36 g-index

46	46	46	1193
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CYP17 inhibitorsâ€"abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nature Reviews Urology, 2014, 11, 32-42.	1.9	132
2	Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17Î±-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. Bioorganic and Medicinal Chemistry, 2008, 16, 1992-2010.	1.4	76
3	Isopropylidene Substitution Increases Activity and Selectivity of Biphenylmethylene 4-Pyridine Type CYP17 Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 5049-5053.	2.9	69
4	Novel CYP17 inhibitors: Synthesis, biological evaluation, structureâ€"activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls. European Journal of Medicinal Chemistry, 2009, 44, 2765-2775.	2.6	63
5	Novel Imidazol-1-ylmethyl Substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as Potent and Selective CYP11B1 Inhibitors for the Treatment of Cushingâ€™s Syndrome. Journal of Medicinal Chemistry, 2012, 55, 6629-6633.	2.9	63
6	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17Î±-hydroxylase-17,20-lyase (CYP17)â€"Part II: Core rigidification and influence of substituents at the methylene bridge. Bioorganic and Medicinal Chemistry, 2008, 16, 7715-7727.	1.4	58
7	Aldosterone Synthase Inhibitors as Promising Treatments for Mineralocorticoid Dependent Cardiovascular and Renal Diseases. Journal of Medicinal Chemistry, 2014, 57, 5011-5022.	2.9	54
8	Cushingâ€™s Syndrome: Development of Highly Potent and Selective CYP11B1 Inhibitors of the (Pyridylmethyl)pyridine Type. Journal of Medicinal Chemistry, 2013, 56, 6022-6032.	2.9	53
9	Selective Dual Inhibitors of CYP19 and CYP11B2: Targeting Cardiovascular Diseases Hiding in the Shadow of Breast Cancer. Journal of Medicinal Chemistry, 2012, 55, 7080-7089.	2.9	51
10	Tetrahydropyrroloquinolinone Type Dual Inhibitors of Aromatase/Aldosterone Synthase as a Novel Strategy for Breast Cancer Patients with Elevated Cardiovascular Risks. Journal of Medicinal Chemistry, 2013, 56, 460-470.	2.9	51
11	Replacement of Imidazolyl by Pyridyl in Biphenylmethylenes Results in Selective CYP17 and Dual CYP17/CYP11B1 Inhibitors for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry, 2010, 53, 5749-5758.	2.9	50
12	Novel Pyridyl- or Isoquinolinyl-Substituted Indolines and Indoles as Potent and Selective Aldosterone Synthase Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 5179-5189.	2.9	48
13	Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences, 2013, 14, 13958-13978.	1.8	45
14	Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases. Journal of Medicinal Chemistry, 2013, 56, 6101-6107.	2.9	40
15	Modulation of Cytochromes P450 with Xanthone-Based Molecules: From Aromatase to Aldosterone Synthase and Steroid 11Î²-Hydroxylase Inhibition. Journal of Medicinal Chemistry, 2013, 56, 1723-1729.	2.9	39
16	The Role of Fluorine Substitution in Biphenyl Methylene Imidazoleâ€Type CYP17 Inhibitors for the Treatment of Prostate Carcinoma. ChemMedChem, 2010, 5, 899-910.	1.6	35
17	Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis. Biochemical and Biophysical Research Communications, 2016, 477, 1005-1010.	1.0	31
18	Synthesis and biological evaluation of imidazolylmethylacridones as cytochrome P-450 enzymes inhibitors. MedChemComm, 2012, 3, 663.	3.5	27

#	Article	IF	Citations
19	Novel Pyridyl Substituted 4,5-Dihydro-[1,2,4]triazolo[4,3-a]quinolines as Potent and Selective Aldosterone Synthase Inhibitors with Improved in Vitro Metabolic Stability. Journal of Medicinal Chemistry, 2015, 58, 2530-2537.	2.9	26
20	CYP17 Inhibitors. Annulations of Additional Rings in Methylene Imidazole Substituted Biphenyls: Synthesis, Biological Evaluation and Molecular Modelling. Archiv Der Pharmazie, 2008, 341, 597-609.	2.1	24
21	3-Pyridyl Substituted Aliphatic Cycles as CYP11B2 Inhibitors: Aromaticity Abolishment of the Core Significantly Increased Selectivity over CYP1A2. PLoS ONE, 2012, 7, e48048.	1.1	23
22	Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: Combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile. Comptes Rendus Chimie, 2009, 12, 1117-1126.	0.2	22
23	Potent 11Î²-Hydroxylase Inhibitors with Inverse Metabolic Stability in Human Plasma and Hepatic S9 Fractions To Promote Wound Healing. Journal of Medicinal Chemistry, 2014, 57, 7811-7817.	2.9	22
24	Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase. European Journal of Medicinal Chemistry, 2015, 90, 788-796.	2.6	22
25	Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushingâ€™s Disease. Journal of Medicinal Chemistry, 2017, 60, 5086-5098.	2.9	22
26	Exploiting the Chromone Scaffold for the Development of Inhibitors of Corticosteroid Biosynthesis. Journal of Medicinal Chemistry, 2016, 59, 2468-2477.	2.9	21
27	1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: A new class of potent and selective aldosterone synthase inhibitors. European Journal of Medicinal Chemistry, 2015, 89, 597-605.	2.6	20
28	Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys. ACS Medicinal Chemistry Letters, 2015, 6, 861-865.	1.3	17
29	Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition. Journal of Steroid Biochemistry and Molecular Biology, 2013, 134, 75-79.	1.2	15
30	Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11Î²-Hydroxylase. European Journal of Medicinal Chemistry, 2015, 96, 139-150.	2.6	13
31	Drug discovery for breast cancer and co-instantaneous cardiovascular disease: what is the future?. Future Medicinal Chemistry, 2013, 5, 359-362.	1.1	11
32	Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing. Bioorganic Chemistry, 2019, 86, 401-409.	2.0	10
33	Chimera induced protein degradation: PROTACs and beyond. European Journal of Medicinal Chemistry, 2020, 206, 112494.	2.6	10
34	Accelerated skin wound healing by selective 11Î²-Hydroxylase (CYP11B1) inhibitors. European Journal of Medicinal Chemistry, 2018, 143, 591-597.	2.6	10
35	Using Acetone/Water Binary Solvent to Enhance the Stability and Bioavailability of Spray Dried Enzalutamide/HPMC-AS Solid Dispersions. Journal of Pharmaceutical Sciences, 2021, 110, 1160-1171.	1.6	9
36	Pharmaceutical Inhibition of Neddylation as Promising Treatments for Various Cancers. Current Topics in Medicinal Chemistry, 2019, 19, 1059-1069.	1.0	8

#	Article	IF	Citations
37	Drifting of heme-coordinating group in imidazolylmethylxanthones leading to improved selective inhibition of CYP11B1. European Journal of Medicinal Chemistry, 2017, 139, 60-67.	2.6	7
38	Therapeutic compounds for Cushingâ€™s syndrome: a patent review (2012-2016). Expert Opinion on Therapeutic Patents, 2016, 26, 1307-1323.	2.4	5
39	Targeting Steroidogenic Cytochromes P450 (CYPs) with 6â€Substituted 1â€Imidazolylmethylxanthones. ChemMedChem, 2016, 11, 1770-1777.	1.6	5
40	The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer. , 2014, , 319-356.		3
41	Design, synthesis and biological evaluation of pyridyl substituted benzoxazepinones as potent and selective inhibitors of aldosterone synthase. Chinese Chemical Letters, 2021, 32, 2327-2332.	4.8	3
42	Unexpected results of a SNAr-reaction. A novel synthetic approach to 1-arylthio-2-naphthols. Tetrahedron Letters, 2013, 54, 6615-6618.	0.7	2